Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL231 vs Ultibro in COPD
NCT06643078Phase 3Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HL231 Solution for Inhalation in chronic obstructive pulmonary disease (COPD), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Dec 2023; status: completed.
02
Drugs
HL231 Solution for Inhalation
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06643078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643078.